Biotech Valuation Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation

CRSP 56.87

-2.3%

Dec 5 3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: opalapril who wrote (1936)	11/3/2000 10:20:27 AM
From: Biomaven	Read Replies (1) of 52153

Well FWIW the Iowa market this morning still has Bush a better than 3:2 favorite. Personally I don't think the election will have that much impact on the biotechs. Overall health care spending would probably be higher under Gore than Bush, which would to some extent offset any Gore moves in the direction of drug price control. Switching back to biotechs, SCIO has an interesting small molecule RA drug - a pre-clinical P38 kinase inhibitor: Message 14692943 Poster presentation at: sciosinc.com Any scientist types care to compare and contrast with the VRTX p38 MAP kinase inhibitor program? I own some SCIO I picked up after the NEJM article on Natrecor came out - I suspect Natrecor will be approved this time around. Peter

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next